Clinical Trials Browser

Phase 2/3 × Genitourinary × 1 year × Clear all

NCT06282588 2026-03-19

THUNDER

Phase 2/3 Recruiting

Prostatic Neoplasms

NCT04628767 2026-03-18

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

Renal Pelvis and Ureter Urothelial Carcinoma

NCT05987241 2026-03-18

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Phase 2/3 Recruiting

Muscle Invasive Bladder Urothelial Carcinoma

NCT06780670 2026-03-16

PSMAcTION

Phase 2/3 Recruiting

Prostatic Neoplasms

NCT07106762 2026-03-10

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT05597878 2026-03-06

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Phase 2/3 Suspended

Agnosia, Prostatic Neoplasms

NCT07129993 2026-03-05

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2/3 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07426055 2026-02-23

PRO-BOOST-LC

Phase 2/3 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07426094 2026-02-23

PRO-BOOST-N

Phase 2/3 Not yet recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT06225596 2026-02-17

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT03070886 2026-01-14

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Phase 2/3 Completed

Stage I Prostate Adenocarcinoma AJCC v7

NCT03258320 2026-01-12

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients

Phase 2/3 Recruiting

Prostatic Neoplasms

NCT00117286 2025-12-18

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

Phase 2/3 Completed

57 enrolled 15 charts

Prostatic Neoplasms

NCT03701581 2025-12-17

4-aminopyridine Treatment for Nerve Injury

Phase 2/3 Recruiting

Erectile Dysfunction, Prostatic Neoplasms

NCT07084909 2025-12-10

HARRIER

Phase 2/3 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05786716 2025-12-02

DETERMINE

Phase 2/3 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther hematologic neoplasmThoracic

Urinary Bladder Neoplasms, Gallbladder Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

NCT06861192 2025-11-18

Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer

Phase 2/3 Recruiting

Prostate CA

NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Phase 2/3 Active not recruiting

190 enrolled 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03772834 2025-10-10

Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer

Phase 2/3 Active not recruiting

Prostatic Neoplasms

NCT04838626 2025-10-07

GuideView

Phase 2/3 Completed

195 enrolled 31 charts

Prostatic Neoplasms

NCT07209878 2025-10-07

68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

Phase 2/3 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07198451 2025-09-30

GEM-IR-NMIBC

Phase 2/3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Recurrence

NCT07156786 2025-09-19

N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial

Phase 2/3 Not yet recruiting

Neoplasms, Acute Kidney Injury

NCT06124976 2025-09-15

Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma

Phase 2/3 Recruiting

Urothelial Carcinoma of the Renal Pelvis and Ureter

NCT03348670 2025-08-17

Drugs-SNPs

Phase 2/3 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT05137561 2025-08-07

PROBIOP

Phase 2/3 Completed

Prostatic Neoplasms

NCT06537154 2025-07-30

NEO-BLAST

Phase 2/3 Recruiting

Urinary Bladder Neoplasms

NCT05920343 2025-07-10

PREVENT-GU

Phase 2/3 Recruiting

Classical hematologyGenitourinary

Urogenital Neoplasms, Urologic Neoplasms, Venous Thromboembolism

NCT06879145 2025-06-18

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

Phase 2/3 Recruiting

Muscular Invasive Bladder Cancer (MIBC)

NCT06972511 2025-05-15

Maximal Tumor Eradication for Oligometastatic Prostate Cancer

Phase 2/3 Recruiting

Oligometastatic Prostate Cancer

NCT03706365 2025-04-20

CYCLONE 2

Phase 2/3 Active not recruiting

393 enrolled 23 charts

Prostatic Neoplasms

NCT03822845 2025-04-17

Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer

Phase 2/3 Completed

6 enrolled 8 charts

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Phase 2/3 Recruiting

Carcinoma, Transitional Cell